抗肿瘤坏死因子治疗与炎症性肠病患者对SARS-CoV-2疫苗的体液反应减弱相关
这项前瞻性研究纳入198例成人炎症性肠病患者,评估初始疫苗接种后及一剂mRNA疫苗加强针后的抗棘突IgG抗体水平。多因素线性回归显示,抗TNF治疗和联合治疗(相较于无免疫抑制)、当前吸烟、病毒载体疫苗(相较于mRNA疫苗)及疫苗接种与抗S抗体检测间隔是log抗S抗体水平的显著预测因素(p < 0.001)。加强针后抗S抗体滴度在非抗TNF组和抗TNF组均出现统计学显著差异。
要点
- 抗TNF治疗(单用或联合治疗)与较低的抗S抗体水平相关。
- mRNA加强针似可提高非抗TNF和抗TNF治疗患者的抗S抗体水平。
- 当前吸烟、病毒载体疫苗及接种与检测间隔也是抗体水平的显著预测因素。
核心结论
- 抗TNF治疗(单用或联合治疗)与较低的抗S抗体水平相关。
- mRNA加强针似可提高非抗TNF和抗TNF治疗患者的抗S抗体水平。
- 制定疫苗接种方案时应特别关注接受抗TNF治疗的患者群体。
研究设计与样本
- 前瞻性研究,纳入198例成人炎症性肠病患者。
- 在初始疫苗接种后及一剂加强针后分别测量抗棘突IgG抗体。
- 建立多因素线性回归模型预测初始完全接种后不同治疗组的抗S抗体滴度。
- 采用双尾Wilcoxon检验比较加强针前后抗S抗体值。
主要发现
- 多因素线性回归识别出抗TNF治疗和联合治疗(相较于无免疫抑制)、当前吸烟、病毒载体疫苗(相较于mRNA疫苗)及疫苗接种与抗S检测间隔为log抗S抗体水平的显著预测因素(p < 0.001)。
- 无免疫抑制组与免疫调节剂组之间无统计学显著差异(p = 0.349)。
- 抗TNF组与联合治疗组之间无统计学显著差异(p = 0.997)。
- mRNA SARS-CoV-2疫苗加强针前后抗S抗体滴度在非抗TNF组和抗TNF组均出现统计学显著差异。
临床怎么用
- 作者认为,制定疫苗接种方案时应特别关注接受抗TNF治疗的患者群体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppressive therapy used in the treatment of inflammatory bowel disease (IBD) is known to reduce vaccine immunogenicity. AIMS: This study aimed to 1) predict the humoral response elicited by SARS-CoV-2 vaccination in IBD patients based on their ongoing treatment and other relevant patient and vaccine characteristics and 2) assess the humoral response to a booster dose of mRNA vaccine. METHODS: We conducted a prospective study in adult IBD patients. Anti-spike (S) IgG antibodies were measured after initial vaccination and again after one booster dose. A multiple linear regression model was created to predict anti-S antibody titer following initial complete vaccination in different therapeutic groups (no immunosuppression, anti-TNF, immunomodulators and combination therapy). A two-tailed Wilcoxon test for two dependent groups was performed to compare anti-S values before and after the booster dose. RESULTS: Our study included 198 IBD patients. The multiple linear regression identified anti-TNF and combination therapy (versus no immunosuppression), current smoking, viral vector (versus mRNA) vaccine and interval between vaccination and anti-S measurement as statistically significant predictors of the log anti-S antibody levels (p < 0.001). No statistically significant differences were found between no immunosuppression and immunomodulators (p = 0.349) and between anti-TNF and combination therapy (p = 0.997). Statistically significant differences for anti-S antibody titer before and after the booster dose of mRNA SARS-CoV-2 vaccine were found, both for non-anti-TNF and anti-TNF groups. CONCLUSIONS: Anti-TNF treatment (either alone or in combination therapy) is associated with lower anti-S antibody levels. Booster mRNA doses seem to increase anti-S both in non-anti-TNF and anti-TNF treated patients. Special attention should be paid to this group of patients when planning vaccination schemes.
引用
- Bordalo Ferreira F, Rafael MA, Coimbra L, et al. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease. Vaccine. 2023. PMID: 37202269. doi:10.1016/j.vaccine.2023.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。